A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings

Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon awakening and lasting into the evening. This pivotal, randomized, double-blind, multicenter, placebo-controlled, phase 3 trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Childress, Ann C., Cutler, Andrew J., Marraffino, Andrea, McDonnell, Mary Ann, Turnbow, John M., Brams, Matthew, DeSousa, Norberto J., Incledon, Bev, Sallee, Floyd R., Wigal, Sharon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041320/
https://www.ncbi.nlm.nih.gov/pubmed/31464511
http://dx.doi.org/10.1089/cap.2019.0070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041320/
https://www.ncbi.nlm.nih.gov/pubmed/31464511
http://dx.doi.org/10.1089/cap.2019.0070

Ejemplares similares